文献速递淋巴瘤

免疫球蛋白克隆内多样性的测定细化了IGHV突变状态在慢性淋巴细胞白血病中的临床影响

Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia.
PubMed 文献 · Leukemia · 2025-06-18

该研究通过针对NGS数据的生物信息学流程,以反辛普森指数(iSI)作为IGHV序列间的多样性度量,将慢性淋巴细胞白血病(CLL)及其他淋巴增殖性疾病(LPD)病例分为IDhigh(iSI≥1.2)与IDlow(iSI<1.2)。在CLL中,IDhigh病例占14.6%,在M-CLL中过表达(P=0.0028);在M-CLL中,IDhigh患者(n=69)较IDlow患者首次治疗时间更长(P=0.015),多因素分析证实ID为独立变量。

要点

  • 所有CLL患者均存在克隆内多样性(ID),但程度不同。
  • IDhigh在M-CLL中过表达(P=0.0028)。
  • M-CLL中IDhigh患者首次治疗时间较IDlow患者更长(P=0.015)。

核心结论

  • 作者提出一种稳健的NGS方案以定量评估CLL中的ID,证明所有CLL患者均存在ID但程度不同,且高程度ID具有临床相关性,可识别预后更好的M-CLL亚组。

研究设计与样本

  • 研究纳入CLL病例(n=983)和其他淋巴增殖性疾病(LPD;n=127),通过针对NGS数据的生物信息学流程,以反辛普森指数(iSI)作为IGHV序列间的多样性度量,将病例分为IDhigh(iSI≥1.2)与IDlow(iSI<1.2)。

主要发现

  • 在CLL中,IDhigh病例占14.6%,在M-CLL中过表达(P=0.0028),而在GC来源的LPD中记录到更高百分比。
  • 在M-CLL(n=396)中,IDhigh患者(n=69)较IDlow患者首次治疗时间更长(P=0.015),多因素分析(n=299)证实ID为独立变量。
  • IDhigh病例的IGHV基因突变具有指示AID/Polη依赖机制持续活动的分子特征;一致地,IDhigh M-CLL表达的AID转录本水平高于IDlow M-CLL(P=0.012)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukemia (CLL) cells may bear mutations in IGHV genes, the 2%-cutoff allowing to discriminate two subsets, unmutated (U)- or mutated (M)-CLL, with different clinical course. IGHV genes may also incorporate additional ongoing mutations, a phenomenon known as intraclonal diversification (ID). Here, through an original bioinformatic workflow for NGS data, we used the inverse Simpson Index (iSI) as diversity measure among IGHV sequences to dichotomize cases with different ID levels into IDhigh (iSI ≥ 1.2) vs. IDlow (iSI < 1.2) both in CLL (n = 983) and in other lymphoproliferative disorders (LPD; n = 127). In CLL, IDhigh cases accounted for 14.6%, overrepresented in M-CLL (P = 0.0028), while higher percentages were documented in GC-derived LPD. In M-CLL (n = 396), IDhigh patients (n = 69) experienced longer time-to-first treatment than IDlow patients (P = 0.015), and multivariate analyses (n = 299) confirmed ID as independent variable. IGHV gene mutations of IDhigh cases had molecular signatures indicating ongoing activity of the AID)/Polη-dependent machinery; consistently, IDhigh M-CLL expressed higher levels of AID transcripts than IDlow M-CLL (P = 0.012). In conclusion, we propose a robust NGS protocol to quantitatively evaluate ID in CLL, demonstrating that: i) all CLL patients presented ID although at various degree; ii) high degree of ID has clinical relevance identifying a M-CLL subset with better outcome.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Vit F, Bittolo T, Zucchetto A, et al. Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia. Leukemia. 2025. PMID: 40533497. doi:10.1038/s41375-025-02650-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。